ROSIGLITAZONE MALEATE AND GLIMEPIRIDE
Clinical safety rating: safe
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and myocardial ischemia.
Rosiglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Glimepiride is a sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels.
| Metabolism | Rosiglitazone: Primarily metabolized by CYP2C8, with minor contribution from CYP2C9. Glimepiride: Metabolized by CYP2C9 to inactive metabolites. |
| Excretion | Rosiglitazone: primarily hepatic metabolism with <1% excreted unchanged in urine; fecal (23%) and urinary (64%) elimination as metabolites. Glimepiride: ~60% excreted in urine as metabolites, ~40% in feces as metabolites. |
| Half-life | Rosiglitazone: 3-4 hours. Glimepiride: 5-9 hours. Clinically, twice-daily dosing for rosiglitazone and once-daily for glimepiride. |
| Protein binding | Rosiglitazone: 99.8% bound to albumin and alpha-1-acid glycoprotein. Glimepiride: >99.5% bound to albumin. |
| Volume of Distribution | Rosiglitazone: 0.26 L/kg; Glimepiride: 0.2 L/kg. Both indicate extensive tissue distribution. |
| Bioavailability | Rosiglitazone: 99%; Glimepiride: 100% after oral administration. |
| Onset of Action | Rosiglitazone: gradual, up to 2 weeks for full glycemic effect; Glimepiride: 1-2 hours after oral administration. |
| Duration of Action | Rosiglitazone: 24 hours; Glimepiride: 24 hours. Note: combination provides sustained glycemic control. |
Oral, initial dose 4 mg rosiglitazone/1 mg glimepiride once daily, titrate based on glycemic response; maximum dose 8 mg rosiglitazone/4 mg glimepiride once daily.
| Dosage form | TABLET |
| Renal impairment | Contraindicated in patients with eGFR <30 mL/min/1.73 m². For eGFR 30-60 mL/min/1.73 m², initiate glimepiride at 1 mg daily; maximum glimepiride dose 4 mg daily. No adjustment for rosiglitazone component. |
| Liver impairment | Contraindicated in Child-Pugh Class B or C. Initiate with caution in Child-Pugh Class A; maximum rosiglitazone dose 4 mg daily. |
| Pediatric use | Not established; safety and efficacy in children <18 years have not been studied. |
| Geriatric use | Start at lower dose of glimepiride (1 mg daily) due to increased risk of hypoglycemia; titrate gradually. Monitor renal function closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and myocardial ischemia.
| FDA category | Animal |
| Breastfeeding | Excretion into human milk is unknown for both components. Rosiglitazone is excreted in rat milk; glimepiride is excreted in rat milk. M/P ratio is not established. The risk to the nursing infant is uncertain; avoid use during breastfeeding due to potential for hypoglycemia and other adverse effects. |
| Teratogenic Risk |
■ FDA Black Box Warning
Rosiglitazone: May cause or exacerbate congestive heart failure; not recommended in patients with symptomatic heart failure. Glimepiride: No black box warning specific to this combination, but sulfonylureas carry increased risk of cardiovascular mortality (based on older studies).
| Common Effects | Weight gain |
| Serious Effects |
Rosiglitazone: NYHA Class III/IV heart failure, severe hepatic impairment, type 1 diabetes, diabetic ketoacidosis. Glimepiride: Hypersensitivity to sulfonylureas, type 1 diabetes, diabetic ketoacidosis.
| Precautions | Rosiglitazone: Fluid retention leading to heart failure, myocardial ischemia (controversial), hepatic effects (monitor LFTs), weight gain, edema. Glimepiride: Hypoglycemia, hemolytic anemia (G6PD deficiency), hypersensitivity reactions. |
Loading safety data…
| Pregnancy Category C: Rosiglitazone has shown fetal harm in animal studies (delayed ossification, embryotoxicity) at doses lower than human exposure. Glimepiride is a sulfonylurea; sulfonylureas have been associated with increased risk of congenital malformations, particularly when used in the first trimester, and prolonged neonatal hypoglycemia when used near term. Use is contraindicated in pregnancy, especially during the second and third trimesters. |
| Fetal Monitoring | If inadvertently used during pregnancy, monitor maternal blood glucose levels closely; assess fetal growth via ultrasound due to risk of macrosomia (maternal hyperglycemia) or growth restriction. Monitor for neonatal hypoglycemia, respiratory distress, and hypocalcemia after delivery if used near term. |
| Fertility Effects | In animal studies, rosiglitazone and glimepiride have not demonstrated significant adverse effects on fertility. In humans, uncontrolled diabetes can impair fertility; improved glycemic control may restore fertility. There are no specific human studies on fertility with the combination. |